A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Launched by JACQUELINE GARCIA, MD ·
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new combination of three medicines—tagraxofusp, azacitidine, and venetoclax—to see if they can safely help control leftover leukemia cells that are too small to see but might cause the cancer to come back in people with Acute Myeloid Leukemia (AML), a type of blood cancer. The main goal is to find out if this combination treatment can reduce the chance of the cancer returning by targeting these hidden leukemia cells.
This study is for adults aged 65 to 74 with AML, regardless of gender. If you join, you will receive the three medicines as part of the treatment to see how well they work together and if they are safe. The trial is currently not yet recruiting participants. This research is important because it aims to improve outcomes for people with AML by focusing on stopping the disease at an early stage before it can come back.
Gender
ALL
Eligibility criteria
About Jacqueline Garcia, Md
Dr. Jacqueline Garcia, MD, is a dedicated clinical trial sponsor with extensive expertise in clinical research and a commitment to advancing medical knowledge through innovative studies. With a strong background in patient care and a focus on translating research findings into practical applications, Dr. Garcia leads initiatives that prioritize patient safety and ethical standards. Her collaborative approach fosters partnerships with research institutions and healthcare professionals, ensuring rigorous methodologies and robust data collection. Through her leadership, Dr. Garcia aims to contribute meaningfully to the development of new therapies and improve outcomes for patients across various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jacqueline Garcia, MD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported